GNH USA

Europe — EMA

Mulpleo (Lusutrombopag)

GNH USA supplies Mulpleo (Lusutrombopag), a thrombopoietin receptor agonist for thrombocytopenia in patients undergoing invasive procedures. Request a quote.

Lusutrombopag

Request sourcing

1
Pack/s

What is Lusutrombopag?

Lusutrombopag, the active ingredient in Mulpleo, is a thrombopoietin receptor agonist presented as a tablet for oral use. It is indicated for thrombocytopenia in patients with chronic liver disease who require invasive procedures.

GNH USA supplies Mulpleo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global markets, ensuring consistent availability of specialty hematology medicines for clinical needs.

What is Lusutrombopag used for?

Lusutrombopag is a thrombopoietin receptor agonist used to manage platelet disorders. - Thrombocytopenia in chronic liver disease undergoing invasive procedures: Increases platelet counts to reduce bleeding risk and enable safe performance of surgeries, biopsies, or other invasive interventions.

What are the side effects of Lusutrombopag?

Lusutrombopag may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache - Nausea - Fatigue - Abdominal pain - Diarrhea - Elevated liver enzymes

Serious or Rare Side Effects: - Thrombotic events (including portal vein thrombosis) - Hepatic decompensation - Severe allergic reactions (anaphylaxis) - Disseminated intravascular coagulation

What precautions apply to Lusutrombopag?

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients closely. - Platelet monitoring: Check platelet counts regularly to avoid excessive elevation. - Active thrombosis: Avoid use in patients with current thrombotic disease. - Severe hepatic impairment: Use with caution; dose adjustments may be required. - Pregnancy and lactation: Consider only if benefits outweigh potential risks. - Storage: Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

What does Lusutrombopag interact with?

Lusutrombopag can interact with other medicines that affect its metabolism or platelet function.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase drug exposure and risk of thrombosis. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce efficacy by lowering plasma levels. - Concurrent use of another thrombopoietin receptor agonist: Increases risk of excessive platelet rise.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, direct oral anticoagulants): May alter bleeding risk; monitor coagulation parameters. - Antiplatelet agents (aspirin, clopidogrel): Potential additive effect on platelet function. - Hepatotoxic drugs (e.g., methotrexate): May compound liver enzyme elevations; monitor liver function tests.

Frequently asked questions

What is Mulpleo used for?+
Mulpleo contains the active ingredient lusutrombopag, a thrombopoietin receptor agonist that is prescribed to increase platelet counts in patients with chronic liver disease who have low platelets and need to undergo invasive procedures such as surgery or biopsy.
How does lusutrombopag work?+
Lusutrombopag binds to the c‑Mpl (thrombopoietin) receptor on megakaryocyte precursors, activating signaling pathways that stimulate megakaryocyte growth and maturation, which in turn raises the production of platelets in the bloodstream.
What is the usual dose of Mulpleo?+
The dosage of Mulpleo is individualized by a qualified prescriber based on the patient’s platelet count, liver function, and procedural timing. The prescribing information provides detailed guidance, and clinicians determine the appropriate regimen for each case.
Is Mulpleo safe to use during pregnancy or breastfeeding?+
Safety data for lusutrombopag in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.
How do I order Mulpleo from GNH USA?+
To request Mulpleo, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Mulpleo compare with other platelet‑raising agents?+
Mulpleo (lusutrombopag) is a small‑molecule oral thrombopoietin receptor agonist, whereas alternatives such as avatrombopag or injectable agents like romiplostim have different routes, dosing schedules, and metabolic pathways. Choice depends on patient preference, liver function, drug‑interaction profile, and clinical setting.
What are the storage requirements for Mulpleo?+
Mulpleo tablets should be stored at ambient temperature below 25 °C, in the original packaging, protected from moisture and direct sunlight. This ensures chemical stability and maintains potency throughout the shelf life.
How is Mulpleo administered?+
Mulpleo is taken orally as a tablet, usually with water. The exact timing relative to the planned invasive procedure is determined by the prescriber, who will also advise on any necessary fasting or concomitant medication adjustments.
What are the most serious risks associated with Mulpleo?+
The most serious risks include thrombotic events such as portal vein thrombosis and hepatic decompensation. Patients should be monitored for signs of abnormal clot formation, worsening liver function, or unexpected bleeding, and therapy should be stopped if severe adverse events occur.
Who should not use Mulpleo?+
Mulpleo is contraindicated in patients with active thrombosis, uncontrolled severe liver disease, or known hypersensitivity to lusutrombopag or any tablet excipients. It should also be avoided in individuals for whom the risk of platelet over‑production outweighs the clinical benefit.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lusutrombopag
Route
Oral Use
Manufacturer
Shionogi B.V.
Origin
EU

Related products

Mulpleo

Mulpleo

Lusutrombopag

Shionogi B.V.
EU
Mulpleo

Mulpleo

Lusutrombopag

Shionogi B.V.
EU
Mulpleo

Mulpleo

Lusutrombopag

Shionogi B.V.
EU